

# A New ICD-10-PCS Code For Extracorporeal Removal of Thrombi and Emboli from Venous System

**Presented by:** John Moriarty, MD  
Vascular & Interventional Radiology  
UCLA Medical Center

**Presented to:** ICD-10-CM/PCS Coordination and  
Maintenance Committee Meeting  
Centers for Medicare & Medicaid Services

**March 18, 2015**



# Agenda

- Coding Issue: Currently no ICD-9 or ICD-10 code to describe this unique intervention
- About Deep Vein Thrombosis
- Traditional Treatments
- Extracorporeal Removal of Thrombi & Emboli
- Rational for ICD-10-PCS
- ICD-10-PCS Code Options
- New Technology Add on Payment
- Questions and Answers




# Venous Blood Clots

- Blood clots (thrombus) that form within a vein
  - DVT: Deep Vein Thrombosis
  - PTS: Post Thrombotic Syndrome
  - VTE: Venous Thromboembolism



# Deep Vein Thrombosis (DVT)



DVTs occur in large venous structures:

- Superior Vena Cava (SVC)
- Inferior Vena Cava (IVC)
- Right Atrium (RA)
- Iliofemoral venous system

DVTs occur as a result of:

- Venous stasis (low or no blood flow)
- Vascular injury
- Hypercoagulable state (cancer, protein C or S deficiency)


# VTE Statistics

- 1 to 3 per 1000 in general population per year
- 900,000-1,000,000 events in US per year
- Third most common cause of cardiovascular mortality
- 20% mortality at 1 year
- In-hospital VTE fatality is 12%, rising to 21% in elderly population



# VTE Incidence

Overall ~1 Million VTE Events per Year in US



AngioVac

Helt JA, et al. *Blood*. 2005;106:267A.

Vortex  
MEDICAL




David Geffen  
School of Medicine

UCLA Health System

UCLA RADIOLOGY

# VTE Mortality

Overall 300,000 VTE Deaths per Year in US - #3 cause



AngioVac

Helt JA, et al. *Blood*. 2005;106:267A.

Murphy SL, et al. Deaths: Preliminary Data for 2010. *National Vital Statistics Reports*; 2012.

Vortex  
MEDICAL



# VTE in 2015

- DVT is very common
- Post Thrombotic Syndrome (PTS) is the most common complication of DVT
- PTS causes large scale:
  - Morbidity
  - Societal cost
  - Reduction in patient QOL
- PTS is inadequately prevented and treated by current regimes





# Post Thrombotic Syndrome (PTS)

- Leg swelling
- Limb pain
- Edema
- Skin Changes
- Leg Ulceration




# Extremely Common

- 20 – 50% of patients with DVT develop PTS despite optimal anticoagulation
  - In most cases, within 12 months
  - Cumulative incidence 10 – 20 years post
- 5 – 10% develop severe PTS...ulcers
- **Probability of developing venous ulcer over 10 years following DVT = 5%**

Kahn, Circ, 2014  
Zidane, Arch Int Med, 2000  
Kahn, Ant Int Med, 2008  
Hencke, J Vac Surg, 2011



# Causes of PTS



# Extreme Societal Cost

- 2 million workdays lost per year in US as a result of leg ulcers
- QOL impairment = COPD, HF
- 2 year initial total per-patient cost of PTS was Canadian \$4527
  - X2 if DVT without PTS
- Estimate mean adjusted annualized cost of developing PTS...**\$11,667**
  - AF \$6697
  - MI \$9716

Bergen, NEJM, 2006

Guarella, JTH, 2011

McDougal, AMJHT, 2006



# Current Treatments for VTE

- Systemic anticoagulation
- Surgical thrombectomy/embolectomy
- Systemic thrombolysis
- Catheter-directed thrombolysis (CDT)



# Anticoagulation

- Glucosaminoglycans (GAGs)
  - Heparin/heparin sulfate
- Vitamin K Agonists (VKAs)
  - Coumadin/warfarin
- Low Molecular Weight Heparin (LMWH)
  - enoxaparin (Lovenox)
- New Oral Anticoagulants (NOACs) approved for:
  - Reduction of recurrent DVT
  - Prevention of PE
    - dabigatran (Pradaxa)
    - rivaroxaban (Xarelto)
    - apixaban (Eliquis)

Prandoni, Ann Intern Med, 2009  
Shulman, NEJM, 1997  
Schulman, NEJM, 2009



# New Oral Anticoagulants (NOACs)

- **DVT Prophylaxis**
  - 2008: RECORD 1,2,3 (rivaroxaban: knee, hip, hip) → superior, fewer bleeds (knees)
  - 2008-10: ADVANCE 1,2,3 (apixaban: knee, knee, hip) → superior with EU dosing, inferior with US dosing
- **VTE (DVT/PE)**
  - 2010 EINSTEIN (rivaroxaban) → noninferior
  - 2012: EINSTEIN-PE (rivaroxaban) → noninferior, fewer bleeds in PE trial
  - 2013: EINSTEIN-EXTEND (rivaroxaban) → superior, more bleeds than placebo
  - AMPLIFY (apixaban) → noninferior, fewer bleeds
  - AMPLIF-EXT (apixaban) → superior, 2.5 mg dose equal placebo bleeds

# Open Vein Hypothesis

- Rapid thrombus elimination and restoration of unobstructed deep venous flow may prevent valvular damage, reflux, venous obstruction and PTS.
  - Meissner (1993): venous segments that developed valvular reflux had longer (2.3 to 7.3 times) endogenous clot clearance than segments that did not ( $P<0.04$ )
  - Prandoni (2005): PTS developed more frequently in proximal DVT patients who had residual venous thrombus or popliteal valvular reflux at 6-mo follow-up (n=180, 47% vs. 23%,  $P<0.01$ )
  - Hull (20056): metaanalysis of 11 randomized DVT treatment trials and found a strong correlation between the amount of residual thrombus after a course of anticoagulant therapy and the subsequent incidence of recurrent VTE





# Systemic Thrombolysis

Significant (18%) or complete clot lysis (45%) can be achieved by giving systemic lysis, but with an unacceptably high risk of bleeding complications (14%)

Goldhaber, Am J med, 1984  
Elliot, BJS, 1979,  
Turpie, Chest, 1990



# Catheter-Directed Thrombolysis (CDT)

- CDT allows higher intrathrombus drug concentration, enhancing drug concentration and reducing total dose
- “CDT has been consistently successful in the removal of thrombus in acute iliofemoral DVT, with approximately 90% of patients experiencing significant thrombolysis.”

Vedantham, JVIR, 2006



# Catheter-Directed Thrombolysis (CDT)



- Urokinase – N/A
- tPA (alteplase)
- rtPA (reteplase)  
– 0.5mg/hr

Semba, JVIR, 2000

Sugimoto, Jvasc Surg, 2003

Bladwin, vasc Endo Surg, 2004



# PRE

# POST



# What else apart from lysis?

- Lysis doesn't work
- Lysis contraindicated
- Acute limb threat

? Faster, Cheaper




# Extracorporeal Removal of Thrombi and Emboli: the AngioVac Procedure


- Typically performed in inpatient hospital setting
- General anesthesia
- Percutaneous procedure with real-time fluoroscopy
- Multidisciplinary team:
  - Interventionalist
  - Surgeon
  - Anesthesiologist
  - Perfusionist



# AngioVac



# Standard AngioVac Cannula and Set Up



Access points are any combination of internal jugular (IJ) or common femoral vein (CFV). The above illustrates AngioVac (right IJ), reinfusion cannula (right CFV).




# RA Thrombus

Right Atrial (RA) thrombus as indicated by the arrow



# IVC Thrombus

Extensive thrombus in the IVC both above and below the IVC filter





# RA Thrombus Removed with AngioVac

## PRE AngioVac

Right Atrial (RA) thrombus as indicated by the arrow

## POST AngioVac

Thrombus removed with AngioVac



# Material Removed with AngioVac

Note the presence of both dark (fresh) thrombus...

...And the lighter, more chronic material



# Evidence

## CASE REPORT

### Hybrid Minimally Invasive Extraction of Atrial Clot Avoids Redo Sternotomy in Jehovah's Witness

*Jain Bhaskara Pillai, FRCS(CTh), FRCSC, Edward R. DeLaney, MS, CCP,  
Nirav C. Patel, MD, and Valavanur A. Subramanian, MD*

**Initial Use of a Large Bore Suction  
Thrombectomy Cannula for the Treatment  
of Massive Inferior Vena Cava (IVC) and  
Iliofemoral Deep Venous Thrombosis (DVT)**  
Shirling Tsai\*, Mark F. Conrad, Virendra Patel,  
Christopher J. Kwolek  
*Massachusetts General Hospital, Boston, MA*



# Vacuum-assisted Debulking of a Prohibitively Large Tricuspid Valve Vegetation Prior to Percutaneous Laser Lead Extraction

<sup>1</sup>JOHN MORIARTY, MD, <sup>2</sup>KOMAL PATEL, MD and <sup>3</sup>JASON BRADFIELD, MD

<sup>1</sup>Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

<sup>2</sup>Department of Anesthesiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

<sup>3</sup>UCLA Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Cardiovasc Intervent Radiol  
DOI 10.1007/s00270-014-0953-7



## CASE REPORT

### AngioVac Aspiration for Paradoxical Emboli Protection through a Fenestrated Fontan During Central Venous Thrombus Manipulation

Ramsey Al-Hakim • Komal Patel • John M. Moriarty

Cardiovasc Intervent Radiol. 2014 Sep 5. [Epub ahead of print]

### A Novel Technique for Endovascular Removal of Large Volume Right Atrial Tumor Thrombus.

Nickel B<sup>1</sup>, McClure T, Moriarty J.

Catheter Cardiovasc Interv. 2014 Jun 27. doi: 10.1002/ccd.25583. [Epub ahead of print]

### Thrombectomy using suction filtration and veno-venous bypass: Single center experience with a novel device.

Donaldson CW<sup>1</sup>, Baker JN, Narayan RL, Provias TS, Rassi AN, Giri JS, Sakhuja R, Weinberg J, Jaff MR, Rosenfield KA.



# Patient Selection Criteria

- When extracorporeal removal of thrombus should be considered:
  - Large thrombus burden not amenable to standard therapy – i.e. thrombolysis or rheolytic therapy (AngioJet)
  - Patient is contraindicated for thrombolytic therapy – i.e. recent surgery, history of stroke (CVA)
  - Patient is a high-risk or non-surgical candidate
    - decision made by the treating or consulting physician



# FDA Status

- Original clearance March, 2009 (K091304, K092486).
- Subsequent clearance March 2014 (K133445).
- Intended for use as a venous drainage cannula during extracorporeal bypass for up to 6 hours and for removal of fresh, soft thrombi or emboli during extracorporeal bypass for up to 6 hours.
- It is for the cannula's expanded indication for removal of fresh, soft thrombi or emboli during extracorporeal bypass for up to 6 hours that the request for ICD-10-PCS code is made.



# Rationale for New ICD-10-PCS Code

- Procedure code needed to describe extracorporeal bypass with removal of thrombi and emboli from venous system
  - When used with prophylactic filtering during bypass surgery
  - When used as stand alone, destination procedure





# ICD-10-PCS Code Options

Description	Comment
Do not create new codes for removal of thrombi and emboli that use cardiopulmonary bypass	This option does nothing to improve the fact that there are no ICD 9 or ICD 10 codes to describe this procedure
Create new codes to capture the prophylactic filtering during cardiopulmonary bypass in section 5A1 and removal of thrombus in the Medical Surgical tables 02C,05C and 06C	<p>If the procedure to remove the thrombus can be coded independent of the prophylactic filtering this option is acceptable.</p> <p>If not, this option does not provide a means of identifying the destination stand alone removal of thrombus.</p>
Create new codes in section X New Technology to identify removal of thrombus using the extracorporeal suction technique	We tentatively support this option but require more detail on this New Technology code section
Create new codes in section X New Technology to identify prophylactic filtering using the extracorporeal suction technique, during surgery that uses cardiopulmonary bypass	We do not support this option because it does not provide a means to code the procedure when performed as a destination therapy



# Conclusion

- This is a novel approach to treat a serious condition
- Not currently coded, not currently forecast for coding under ICD-10-PCS
- Hospitals need code for identification of procedure:
  - Data Capture
  - Economic Analysis
  - Outcomes
  - Application for NTAP will be made
  - We request consideration of new code(s) for 2017 or as soon as code freeze is lifted



# Questions/Answers/Discussion

